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Loss-of-function mutations of the PAX8 gene are considered to mainly cause congenital hypothyroidism (CH) due to thyroid
hypoplasia. However, some patients with PAX8 mutation have demonstrated a normal-sized thyroid gland. Here we report a CH
patient caused by a PAX8 mutation, which manifested as iodide transport defect (ITD). Hypothyroidism was detected by neonatal
screening and L-thyroxine replacement was started immediately. Although 123I scintigraphy at 5 years of age showed that the
thyroid gland was in the normal position and of small size, his iodide trapping was low. The ratio of the saliva/plasma radioactive
iodide was low. He did not have goiter; however laboratory ﬁndings suggested that he had partial ITD. Gene analyses showed
that the sodium/iodide symporter (NIS) gene was normal; instead, a mutation in the PAX8 gene causing R31H substitution was
identiﬁed. The present report demonstrates that individuals with defective PAX8 can have partial ITD, and thus genetic analysis is
useful for diﬀerential diagnosis.
1.Introduction
Congenital hypothyroidism (CH) is the most common
congenital endocrine disorder and occurs at rate of 1 in
3000–4000 births [1]. The causes of CH can be classiﬁed into
two groups: thyroid developmental defects (thyroid dysge-
nesis) and inborn errors of thyroid hormone biosynthesis
(dyshormonogenesis). Several genes responsible for thyroid
dysgenesis have been identiﬁed such as TSHβ-subunit, TSH
receptor, the Gs α-subunit, TTF-1, TTF-2, GLIS3, and PAX8
[2]. Among them, PAX8 is a paired domain transcription
factorandisexpressedinthedeveloping thyroid,kidney,and
several areas of the central nervous system [3]. In addition to
its role in normal thyroid development, PAX8 regulates the
expression of genes encoding thyroglobulin (TG), thyroid
peroxidase (TPO), and the sodium-iodide symporter (NIS)
by binding to their promoter regions through its 128-amino
acid paired domain [4, 5]. To date, several mutations of
the PAX8 gene have been identiﬁed in CH patients [6–12].
Most of these mutations have caused thyroid dysgenesis;
however, some patients with PAX8 mutation have a normal-
s i z e dt h y r o i dg l a n d[ 9, 10].
Iodidetransportdefect(ITD)isararedisordercharacter-
izedbyaninabilityofthethyroidtomaintainaconcentration
diﬀerence of readily exchangeable iodide between the plasma
andthethyroid.DiagnosticcriteriaforITDincludeavariable
degree of CH and goiter, low or absent radioiodide uptake,
as determined by thyroid scintigraphy, and low iodide saliva
to plasma (S/P) ratio [13, 14]. This disease is caused by
mutations of the NIS gene [13–17].
Here we report that a patient with a PAX8 mutation
showed low iodide S/P ratio. The PAX8 mutation in this
patient manifested as CH due to ITD.
2.CaseReport
A male infant was born after full-term gestation by normal
vaginal delivery from nonconsanguineous parents. His birth
weight was 3342g. The family history revealed no thyroid
disease. There were no abnormal physical ﬁndings; however,
neonatal mass screening using ﬁlter paper for congenital
hypothyroidism at the age of 6 days showed a high level
of thyroid stimulating hormone (TSH) (62.8mU/L, normal2 Journal of Thyroid Research
Table 1: Laboratory ﬁndings in the patient.
Values of ﬁlter paper at neonatal screening
TSH (mU/L) (normal range 0.1 ∼ 10) 62.8
Values at the time of the ﬁrst evaluation (Serum)
17 days of age
TSH (mU/L) (normal range 0.34 ∼ 3.5) 202.7
T4 (nmol/L) (normal range 59.2 ∼ 161.2) 91.2
T3 (nmol/L) (normal range 1.22 ∼ 2.76) 1.88
123I thyroid scan (%)a at 1, 3, 24h 4.8, 5.8, 2.9
Saliva/Serum 123ratiob at 2h and 4h 4.5, 3.8
Thyroid scan was performed at age of 6 years a, normal above 10%–35%, b,
normal above 20.
<10mU/L). The patient was referred to our hospital at
the age of 17 days for further evaluation. At that time
his body weight was 3950g. Physical examination did not
show any abnormal ﬁndings including goiter. Biochem-
ical evaluation revealed that the serum TSH level was
202.7mU/L, thyroxine, 91.3nmol/L, and triiodothyronine,
1.88nmol/L (Table 1). He was treated with levothyroxine
(L-T4) at that time. At the age of 5 years, he underwent
123I scintigraphy after the discontinuing L-T4 treatment for
one month. Although 123I scintigraphy showed a normally
located thyroid gland, his 1-, 3-, and 24-hour 123Iu p t a k e
values were 4.8%, 5.8%, and 2.9%, respectively (normal
range, 10%–30%). 123I S/P ratios at 2 and 4 hours were 4.5
and 3.8, respectively (normal >20) (Table 1). He did not
have goiter; however, his diagnosis was considered to be
partialITDbasedonlowthyroidaliodideuptakeandlowS/P
ratio. The patient is currently 23 years old, and he has never
developed goiter during follow-up.
3. Method
After obtaining written consent from the patient and the
patient’s parent, genomic DNA was extracted from periph-
eral blood lymphocytes. The NIS and PAX8 genes were
ampliﬁed by polymerase chain reaction (PCR) according
to previously-described methods [6, 17]. After PCR ampli-
ﬁcation, the ampliﬁed products were subjected to direct
sequencing.
4. Results
Analysis of the NIS gene revealed no nucleotide changes
in the coding region nor in the exon-intron boundaries.
Upon analysis of the PAX8 gene, we identiﬁed the patient
washeterozygous for an arginine (CGC)-to-histidine (CAC)
substitution at codon 31 (R31H), which was previously
reported in a patient with CH [6]( Figure 1).
5. Discussion
In the present study, we reported a Japanese patient with
R31H substitution in the PAX8 protein. Since the arginine
at residue 31 is located in the paired domain in the PAX8
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Figure 1: Sequence analysis demonstrated a C to A transition in the
patient. This change substitutes histidine for arginine at residue 31
in the paired domain denoted by the arrow. WT: wild-type.
protein and is conserved among species, this amino acid
substitution is thought to impair its DNA-binding activity,
resulting in loss of function. It is of interest that a mutation
at this residue was previously found in one Italian patient
and one Japanese patient [6, 7]. These two patients were
diagnosed as having thyroid hypoplasia as determined by
ultrasonographic examination. We also identiﬁed R31H in
another Japanese CH patient who had hypoplastic thyroid
(unpublished data). To determine whether or not substitu-
tionofthisarginineisfrequentamongJapanesepatientswith
CH, further analysis is required.
Defective mutations of the PAX8 gene have been consid-
ered to mainly cause thyroid hypoplasia. However, clinical
heterogeneity has been observed among patients and even
in the same family [9, 10]. One patient who had S54G
substitution in of the PAX8 protein had organiﬁcation defect
and a normal-sized thyroid [10]. Since PAX8 plays a critical
role in TPO expression during thyroid development [2, 4],
impaired TPO gene expression due to PAX8 dysfunction
may have led to organiﬁcation defect in that patient. In this
context, it may be possible that NIS expression is aﬀected by
mutations of the PAX8 gene, because a PAX8 binding site
wasfoundinthefar-upstreamenhancerregionofthehuman
NIS gene and PAX8 was required for activation of NIS gene
expression in the thyroid [18]. As mentioned earlier, the
hallmarks of ITD are markedly reduced or absent thyroidal
uptake of radioiodide and reduced iodide S/P ratio. AbsenceJournal of Thyroid Research 3
of thyroidal iodide uptake is a typical feature of thyroid
agenesis, and thus diagnosis is erroneously assigned to some
patients with iodide trapping defect, especially when goiter
was not present. Szinnai et al. [14] summarized the clinical
features, laboratory ﬁndings, and mutations of the NIS gene
in patients with ITD. Among these 31 patients, radioiodide
uptake ranged from <1% to 4.8% and the iodide S/P
ratio ranged from 0.94 to 5.2. Regarding goiter, 18 patients
developed goiter and its diagnosis was made at a median
age of 11 years. In our patient, the value of radioiodide
uptake was higher than that in previously reported patients.
However, the iodide S/P ratio in our patient was low. An
iodide S/P ratio in the vicinity of 1 is considered to be the
consequence of complete ITD while an iodide S/P ratio of up
to 20 is considered to represent partial ITD [13]. Therefore,
we initially speculated that the cause of CH in our patient
was partial ITD due to defective NIS. However, sequence
analysis showed that the NIS gene was normal; instead a
mutation causing R31H in the PAX8 protein was found. As
mentioned earlier, PAX8 gene expression during the fetal
period is observed in the developing thyroid and kidney
during human development [3]; however, its expression in
salivary glands has not been examined. It is tempting to
speculate that PAX8 is expressed and enhances NIS gene
expression during embryogenesis in the human salivary
glands similar to in the thyroid gland. Thus, PAX8 mutation
may impair NIS function not only in the thyroid but also in
the salivary glands. This possibility must be studied further.
In conclusion, we reported a patient with a mutation
causing R31H substitution in the PAX8 protein, which
manifested as partial ITD.
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